OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation
Peter A. LeWitt, Aaron Ellenbogen, Daniel Burdick, et al.
Clinical Parkinsonism & Related Disorders (2023) Vol. 8, pp. 100197-100197
Open Access | Times Cited: 7
Peter A. LeWitt, Aaron Ellenbogen, Daniel Burdick, et al.
Clinical Parkinsonism & Related Disorders (2023) Vol. 8, pp. 100197-100197
Open Access | Times Cited: 7
Showing 7 citing articles:
IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease
Robert A. Hauser, Alberto J. Espay, Aaron Ellenbogen, et al.
JAMA Neurology (2023) Vol. 80, Iss. 10, pp. 1062-1062
Open Access | Times Cited: 12
Robert A. Hauser, Alberto J. Espay, Aaron Ellenbogen, et al.
JAMA Neurology (2023) Vol. 80, Iss. 10, pp. 1062-1062
Open Access | Times Cited: 12
Rethinking the Role of Continuous Dopaminergic Stimulation in Parkinson Disease Therapy
Peter A. LeWitt
Parkinsonism & Related Disorders (2025), pp. 107354-107354
Closed Access
Peter A. LeWitt
Parkinsonism & Related Disorders (2025), pp. 107354-107354
Closed Access
Advances in the Pharmacological Management of Parkinson’s Disease
Derek G. Power, Grace F. Crotty
Current Treatment Options in Neurology (2025) Vol. 27, Iss. 1
Closed Access
Derek G. Power, Grace F. Crotty
Current Treatment Options in Neurology (2025) Vol. 27, Iss. 1
Closed Access
Levodopa treatment: impacts and mechanisms throughout Parkinson’s disease progression
Peter Riederer, Sabrina Strobel, Toshiharu Nagatsu, et al.
Journal of Neural Transmission (2025)
Open Access
Peter Riederer, Sabrina Strobel, Toshiharu Nagatsu, et al.
Journal of Neural Transmission (2025)
Open Access
Model-based optimization of controlled release formulation of levodopa for Parkinson’s disease
Yehuda Arav, Assaf Zohar
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 5
Yehuda Arav, Assaf Zohar
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 5
Duration of “Good On” Time per Dose: Immediate-Release Carbidopa-Levodopa vs Extended-Release Carbidopa-Levodopa (IPX203, CREXONT®)
Robert A. Hauser, Hubert H. Fernandez, Joohi Jimenez‐Shahed, et al.
Parkinsonism & Related Disorders (2024) Vol. 131, pp. 107239-107239
Closed Access
Robert A. Hauser, Hubert H. Fernandez, Joohi Jimenez‐Shahed, et al.
Parkinsonism & Related Disorders (2024) Vol. 131, pp. 107239-107239
Closed Access
Continuous subcutaneous levodopa-carbidopa for the treatment of advanced Parkinson’s disease: is it an improvement on other delivery?
Sheila A Doggrell
Expert Opinion on Drug Delivery (2023) Vol. 20, Iss. 9, pp. 1189-1199
Closed Access | Times Cited: 1
Sheila A Doggrell
Expert Opinion on Drug Delivery (2023) Vol. 20, Iss. 9, pp. 1189-1199
Closed Access | Times Cited: 1
